Top Tweets for #RASOLUTE

1 day ago

🚨 #RASolute-302: Evaluating the Side Effect Profile of Daraxonrasib 🔑 Common TRAEs: rash, mucositis/stomatitis, nausea, vomiting, diarrhea ✅ Improved QoL & pain control #gism #OncTwitter #MedTwitter #pcsm #MedX @ShirajSenMDPhD #GIOnc 🎥Full video 👇 https://t.co/xp4b3XZdnZ

311

OncUpdates

@OncUpdates

5 days ago

🚨 Transformational Data: #HERIZON-GEA-01 & #RASolute-302 🎙️ @GIcancerDoc & @ShrutiPatelMD: ✅ HERIZON-GEA-01: poised for approval in HER2+ mGEA ✅ RASolute-302: Daraxonrasib DOUBLES OS in met #PancreaticCancer #gism #OncTwitter #MedTwitter Full 🗣️👇 https://t.co/7njh64lhMu

445

OncUpdates

@OncUpdates

7 days ago

🚨 #RASolute-302 & Its Impact on #GI #Oncology @Charbel_matar1 @Deebacca ✅ Median OS (13.2 vs 6.7 months) ✅ Benefits across RAS mutant & wild-type! 👏Standing ovation at #ASCO26! Watch full 🗣️👇 #PancreaticCancer #gism #OncTwitter #MedTwitter #pcsm https://t.co/rs7A239vte

426

Big Pharma Sharma

@BigPharmaSharma

7 days ago

𝐃𝐚𝐫𝐚𝐱𝐨𝐧𝐫𝐚𝐬𝐢𝐛: @RevMedicines presented the full #RASolute 302 dataset at @ASCO plenary. 60% reduction in death risk. 13.2 versus 6.7 months OS. Hazard ratio 0.40. In pancreatic cancer, where nothing works. Standing ovation in the auditorium. Non-biotech friends & family are bringing this up unprompted. A different kind of signal.

BigPharmaSharma's tweet photo. 𝐃𝐚𝐫𝐚𝐱𝐨𝐧𝐫𝐚𝐬𝐢𝐛:

@RevMedicines presented the full #RASolute 302 dataset at @ASCO plenary.

60% reduction in death risk.
13.2 versus 6.7 months OS.
Hazard ratio 0.40.

In pancreatic cancer, where nothing works.

Standing ovation in the auditorium.
Non-biotech friends & family are bringing this up unprompted.

A different kind of signal.

136

TwoOncDocs @TwoOncDocs

15 days ago

That’s a wrap for #ASCO26 💕 We are excited to dive in to our key takeaways in next week’s episode including some of the plenary sessions (#RASolute ‼️#SARC1, #PROTREUS) & more 📅 & save the date for our #ASH26 free heme board review session for trainees Dec 11🩸 @OncBrothers

TwoOncDocs's tweet photo. That’s a wrap for #ASCO26 💕

We are excited to dive in to our key takeaways in next week’s episode including some of the plenary sessions (#RASolute ‼️#SARC1, #PROTREUS) & more

📅 & save the date for our #ASH26 free heme board review session for trainees Dec 11🩸 @OncBrothers https://t.co/A4NYkL3BY6

GI NURSES CONNECT powered by COR2ED

@ginursesconnect

15 days ago

📣#GICancer highlights from #ASCO26! Prof. @HPrenen shares his expert insights on key #ColorectalCancer, #PancreaticCancer & #LiverCancer #trialdata from #EMERALD-3, #BREAKWATER & #RASolute 302 How will these data impact clinical practice? Watch his video to find out! 🤝 Programme endorsed by @WarOnCancer 📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #lungcancer, #ProstateCancer & #BreastCancer >> https://t.co/RLiQL3weSL This educational programme is supported by COR2ED #MedEd #HCC #CRCSM #CRC #CancerNurses

HCC CONNECT powered by COR2ED

@hccconnectinfo

15 days ago

📣#GICancer highlights from #ASCO26! Prof. @HPrenen shares his expert insights on key #ColorectalCancer, #PancreaticCancer & #LiverCancer #trialdata from #EMERALD-3, #BREAKWATER & #RASolute 302 How will these data impact clinical practice? Watch his video to find out! 🤝 Programme endorsed by @WarOnCancer 📺See more updates from @ASCO in HER2-mutant #NSCLC, #lungcancer, #ProstateCancer & #BreastCancer >> https://t.co/xW9wCMNBxi This educational programme is supported by COR2ED. #MedEd #HCC #CRCSM #CRC #CancerNurses

223

GI CONNECT powered by COR2ED

@giconnectInfo

15 days ago

📣#GICancer highlights from #ASCO26! Prof. @HPrenen shares his expert insights on key #ColorectalCancer, #PancreaticCancer & #LiverCancer #trialdata from #EMERALD-3, #BREAKWATER & #RASolute 302 How will these data impact clinical practice? Watch his video to find out! 🤝 Programme endorsed by @WarOnCancer 📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #lungcancer, #ProstateCancer & #BreastCancer ⬇️ https://t.co/fBXcXcgl6P This educational programme is supported by COR2ED. #MedEd #HCC #CRCSM #CRC #CancerNurses

144

MedChemExpress

@MedChemExpress

15 days ago

🧬Molecule of the Moment from #ASCO2026 | #Daraxonrasib, a pan-#RAS inhibitor, delivered a significant survival benefit in previously treated metastatic pancreatic ductal adenocarcinoma (#PDAC). 📊 Phase 3 #RASolute 302: 🔹 Median OS: 13.2 vs 6.7 months 🔹 Median PFS: 7.2 vs 3.6 months 🔹 Significant improvement over standard chemotherapy RAS was once considered "undruggable". Today, a RAS-targeted therapy is showing a near doubling of overall survival. 🌟MedChemExpress offers daraxonrasib for research use only: https://t.co/or24dj5iUH #PancreaticCancer #KRAS #Oncology #CancerResearch #DrugDiscovery #TargetedTherapy #Biotech #ASCO #ASCO26

MedChemExpress's tweet photo. 🧬Molecule of the Moment from #ASCO2026 | #Daraxonrasib, a pan-#RAS inhibitor, delivered a significant survival benefit in previously treated metastatic pancreatic ductal adenocarcinoma (#PDAC).

📊 Phase 3 #RASolute 302:
🔹 Median OS: 13.2 vs 6.7 months
🔹 Median PFS: 7.2 vs 3.6 months
🔹 Significant improvement over standard chemotherapy

RAS was once considered "undruggable".
Today, a RAS-targeted therapy is showing a near doubling of overall survival.

🌟MedChemExpress offers daraxonrasib for research use only: https://t.co/or24dj5iUH

#PancreaticCancer #KRAS #Oncology #CancerResearch #DrugDiscovery #TargetedTherapy #Biotech #ASCO #ASCO26

597

Eleftheria Atalla, MD @EllieAtalla

16 days ago

#RASolute-302: The most awaited plenary session of #ASCO206, changing the landscape of metastatic pancreatic cancer treatment. What an incredible time to be an oncologist 🙌

Oncology Brothers

@OncBrothers

16 days ago

5. RASolute-302: Daraxonrasib (pan-RAS inhibitor) vs. chemo in 2L metastatic pancreatic adenocarcinoma: - Majority of PDAC harbor RAS mutation (more than 90%) - mOS (in all comers): 13.2mos vs. 6.7mos (HR: 0.40) - Gr ≥ 3 AEs: 62% vs. 70% - New SoC/paradigm shifting!! 6/6 https://t.co/ZkkRT84uQ7

OncBrothers's tweet photo. 5. RASolute-302: Daraxonrasib (pan-RAS inhibitor) vs. chemo in 2L metastatic pancreatic adenocarcinoma:

- Majority of PDAC harbor RAS mutation (more than 90%)
- mOS (in all comers): 13.2mos vs. 6.7mos (HR: 0.40)
- Gr ≥ 3 AEs: 62% vs. 70%
- New SoC/paradigm shifting!!

6/6

https://t.co/ZkkRT84uQ7

26K

376

Agrima Mian

@AgrimaMianMD

16 days ago

Moments like today at #ASCO26 remind you why oncology is such an extraordinary field. What an absolute privilege to witness advances like #RASOLUTE-302 in real time. #RAS_ON @MSK_DeptOfMed @RevMedicines @DanaFarber #mPDAC

Yüksel Ürün

@DrYukselUrun

16 days ago

This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 @DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

277

213

193K

TwoOncDocs @TwoOncDocs

16 days ago · Chicago

Standing ovation for a ***breakthrough*** in #pancreaticcancer 🥹🥹🥹 #RASolute today presented at #ASCO26: Daraxonrasib DOUBLES the median overall survival in metastatic pancreatic cancer w/ +w/o RAS (mOS 13.2 mo vs. 6.6 mo) A HUGE advance in one of the most lethal cancers 💜

OncUpdates

@OncUpdates

16 days ago

🔥GAME CHANGER in #PancreaticCancer-#ASCO26 Plenary #RASolute 302 Ph3 ✅ Median OS 13.2 vs 6.7 months ✅ Met all primary +key secondary endpoints (OS,PFS,ORR) 🔑Results support daraxonrasib as new SOC in 2L+mPDAC. @ASCO @OncBrothers @DrShubhamPant #gism #OncTwitter #MedTwitter

OncUpdates's tweet photo. 🔥GAME CHANGER in #PancreaticCancer-#ASCO26 Plenary

#RASolute 302 Ph3
✅ Median OS 13.2 vs 6.7 months
✅ Met all primary +key secondary endpoints (OS,PFS,ORR)

🔑Results support daraxonrasib as new SOC in 2L+mPDAC.
@ASCO @OncBrothers @DrShubhamPant #gism #OncTwitter #MedTwitter https://t.co/QMUewomA5B

207

Dr Joseph McCollom DO

@realbowtiedoc

18 days ago

A thrill to be at #ASCO26 where the best in #GIonc will be presented. To have an earth shattering #plenary with #RASOLUTE will be a dream come true but many other highlights #Fight302 🥊 #Emerald3 💎 #PUMP ⛽️ #BREAKWATER 🌊. So much to love! #OncoAlertAF @FadiHaddad_MD @Abdallah81MD @Erman_Akkus @bavilima @acampsmalea @DrFMartinelli @Dr_Ivanoncologo @orellanauro @FernandoOnco @Lucarecco @HHorinouchi @ElisaAgostinett @to_be_elizabeth @BRicciutiMD @nataliagandur @GaiaGriguolo @JankovicK @weoncologists @OncoReporte @GIMedOnc @MarioBalsaMD @DrMirallas @OscarTahuahua @DrRishabhOnco @UOzkerim @Onco_Cifu88 @DraMartinezLago @DaisukeKotani

OncoAlert

@OncoAlert

19 days ago

The OncoAlert🚨 GI faculty’s TOP 10 abstracts In GI Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior experts across #ColorectalCancer #ColonCancer #LiverCancer #PancreaticCancer and more A snapshot of what will shape GI oncology at #ASCO26 👇 🚨 OncoAlert Top 10 — #GIcancer at #ASCO26 1️⃣ LBA5 | RASOLUTE 302 — Daraxonrasib vs chemo in previously treated metastatic pancreatic adenocarcinoma 2️⃣ #4017 | FIGHT-302 — Pemigatinib in untreated unresectable/metastatic FGFR2-rearranged cholangiocarcinoma (Ph3) 3️⃣ LBA4000 | EMERALD-3 — Tremelimumab + durvalumab + lenvatinib + TACE in unresectable HCC (Ph3) 4️⃣ #3506 | PUMP Trial — Adjuvant HAIP floxuridine in resectable colorectal liver metastases 5️⃣ LBA3500 | CIRCULATE — ctDNA-guided adjuvant therapy in Stage II colon cancer 6️⃣ LBA3503 | BREAKWATER — Encorafenib + cetuximab + FOLFIRI as 1L in BRAF V600E mCRC (Ph3) 7️⃣ LBA3508 | EPISODE-III — Adjuvant aspirin vs placebo in Stage III CRC post-resection (Ph3) 8️⃣ #3505 — Trastuzumab rezetecan vs SOC in chemo-refractory HER2+ advanced CRC (Ph3) 9️⃣ #4006 | ATTRACTION-6 — Nivo + ipi + chemo as 1L in HER2− advanced gastric/GEJ cancer 🔟 #3504 | SWOG S2107 — Encorafenib + cetuximab + nivo in MSS BRAF V600E mCRC (Ph2) Leads @realbowtiedoc @p_ciracimd @WeOncologists Senior faculty @CathyEngMD @ARosen380 @GillSharlene @BenWestphalen @graokane Participating AF @DrVilmaPBarcia @Erman_Akkus @GIMedOnc

$OncoAlert's tweet photo. The OncoAlert🚨 GI faculty’s TOP 10 abstracts In GI Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior experts across #ColorectalCancer #ColonCancer #LiverCancer #PancreaticCancer and more A snapshot of what will shape GI oncology at #ASCO26 👇 🚨 OncoAlert Top 10 — #GIcancer at #ASCO26 1️⃣ LBA5 | RASOLUTE 302 — Daraxonrasib vs chemo in previously treated metastatic pancreatic adenocarcinoma 2️⃣ #4017 | FIGHT-302 — Pemigatinib in untreated unresectable/metastatic FGFR2-rearranged cholangiocarcinoma (Ph3) 3️⃣ LBA4000 | EMERALD-3 — Tremelimumab + durvalumab + lenvatinib + TACE in unresectable HCC (Ph3) 4️⃣ #3506 | PUMP Trial — Adjuvant HAIP floxuridine in resectable colorectal liver metastases 5️⃣ LBA3500 | CIRCULATE — ctDNA-guided adjuvant therapy in Stage II colon cancer 6️⃣ LBA3503 | BREAKWATER — Encorafenib + cetuximab + FOLFIRI as 1L in BRAF V600E mCRC (Ph3) 7️⃣ LBA3508 | EPISODE-III — Adjuvant aspirin vs placebo in Stage III CRC post-resection (Ph3) 8️⃣ #3505 — Trastuzumab rezetecan vs SOC in chemo-refractory HER2+ advanced CRC (Ph3) 9️⃣ #4006 | ATTRACTION-6 — Nivo + ipi + chemo as 1L in HER2− advanced gastric/GEJ cancer 🔟 #3504 | SWOG S2107 — Encorafenib + cetuximab + nivo in MSS BRAF V600E mCRC (Ph2) Leads @realbowtiedoc @p_ciracimd @WeOncologists Senior faculty @CathyEngMD @ARosen380 @GillSharlene @BenWestphalen @graokane Participating AF @DrVilmaPBarcia @Erman_Akkus @GIMedOnc$

865

Top Tweets for #RASOLUTE

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users